Search Results - "NAKATA, MASAO"

Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer by Shimizu, Katsuhiko, Okita, Riki, Saisho, Shinsuke, Maeda, A I, Nojima, Yuji, Nakata, Masao

“…There is no clear evidence in the literature regarding the regulation of programmed cell death-ligand 1 (PD-L1) expression by cyclo-oxygenase-2 (COX2). In this…”
Get full text

Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201 by Yamamoto, Hiromasa, Soh, Junichi, Okumura, Norihito, Suzuki, Hiroyuki, Nakata, Masao, Fujiwara, Toshiya, Gemba, Kenichi, Sano, Isao, Fujinaga, Takuji, Kataoka, Masafumi, Terazaki, Yasuhiro, Fujimoto, Nobukazu, Kataoka, Kazuhiko, Kosaka, Shinji, Yamashita, Motohiro, Inokawa, Hidetoshi, Inoue, Masaaki, Nakamura, Hiroshige, Yamashita, Yoshinori, Hotta, Katsuyuki, Yoshioka, Hiroshige, Morita, Satoshi, Matsuo, Keitaro, Sakamoto, Junichi, Date, Hiroshi, Toyooka, Shinichi

“…It is shown that the postoperative adjuvant chemotherapy for non-small cell lung cancer (NSCLC) was associated with survival benefit in an elderly population…”
Get full text

Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer by Okita, Riki, Maeda, Ai, Shimizu, Katsuhiko, Nojima, Yuji, Saisho, Shinsuke, Nakata, Masao

“…Platinum‑based chemotherapy improves the clinical outcome of patients with non‑small cell lung cancer (NSCLC), although tumors often become refractory after…”
Get full text

Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer by Okita, Riki, Maeda, Ai, Shimizu, Katsuhiko, Nojima, Yuji, Saisho, Shinsuke, Nakata, Masao

“…UL16-binding protein (ULBP) 1-6 and MHC class I chain-related molecule A and B (MICA/B) are NK group 2, member D (NKG2D) ligands, which are specifically…”
Get full text

A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer by Toyooka, Shinichi, Okumura, Norihito, Nakamura, Hiroshige, Nakata, Masao, Yamashita, Motohiro, Tada, Hirohito, Kajiwara, Shinsuke, Watanabe, Naoki, Okada, Morihito, Sakamoto, Junichi, Aoe, Motoi, Soh, Junichi, Miyoshi, Shinichiro, Hotta, Katsuyuki, Matsuo, Keitaro, Date, Hiroshi

“…We conducted a randomized controlled study to compare the survival benefit of paclitaxel plus carboplatin and oral uracil-tegafur (UFT) as adjuvant…”
Get more information

Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer by Shimizu, Katsuhiko, Okita, Riki, Saisho, Shinsuke, Yukawa, Takuro, Maeda, Ai, Nojima, Yuji, Nakata, Masao

“…Objective The maximal standardized uptake value (SUVmax) of pulmonary lesions on dual-time-point (DTP) fluorodeoxyglucose positron emission tomography…”
Get full text

Tofacitinib overcomes an IFNγ‐induced decrease in NK cell‐mediated cytotoxicity via the regulation of immune‐related molecules in LC‐2/ad by Okita, Riki, Shimizu, Katsuhiko, Nojima, Yuji, Saisho, Shinsuke, Nakata, Masao

“…Background Immune checkpoint inhibitors targeting the programmed cell death‐1 (PD‐1)/PD‐1 ligand 1 (PD‐L1) axis have shown promising results in patients with…”
Get full text

Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings by Shimizu, Katsuhiko, Okita, Riki, Saisho, Shinsuke, Maeda, Ai, Nojima, Yuji, Nakata, Masao

“…We performed an analysis to clarify differences in clinicopathological and molecular features of lung invasive mucinous adenocarcinoma (IMA) based on computed…”
Get full text

Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301 by Okumura, Norihito, Soh, Junichi, Suzuki, Hiroyuki, Nakata, Masao, Fujiwara, Toshiya, Nakamura, Hiroshige, Sonobe, Makoto, Fujinaga, Takuji, Kataoka, Kazuhiko, Gemba, Kenichi, Kataoka, Masafumi, Hotta, Katsuyuki, Yoshioka, Hiroshige, Matsuo, Keitaro, Sakamoto, Junichi, Date, Hiroshi, Toyooka, Shinichi

“…The aim of this multicenter, randomized phase II study was to analyze the feasibility and safety of alternate-day S-1, an oral fluoropyrimidine, for adjuvant…”
Get full text

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells by Okita, Riki, Wolf, Diana, Yasuda, Koichiro, Maeda, Ai, Yukawa, Takuro, Saisho, Shinsuke, Shimizu, Katsuhiko, Yamaguchi, Yoshiyuki, Oka, Mikio, Nakayama, Eiichi, Lundqvist, Andreas, Kiessling, Rolf, Seliger, Barbara, Nakata, Masao

“…Several cytotoxic anticancer drugs inhibit DNA replication and/or mitosis, while EGFR tyrosine kinase inhibitors inactivate EGFR signalling in cancer cell…”
Get full text

Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer by Shimizu, Katsuhiko, Okita, Riki, Saisho, Shinsuke, Maeda, Ai, Nojima, Yuji, Nakata, Masao

“…Numerous studies conducted until date have reported that the chemotherapy regimen could affect the programmed cell death ligand 1 (PD-L1) expression status in…”
Get full text

Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial by Soh, Junichi, Toyooka, Shinichi, Okumura, Norihito, Nakamura, Hiroshige, Nakata, Masao, Yamashita, Motohiro, Sakamoto, Junichi, Aoe, Motoi, Hotta, Katsuyuki, Morita, Satoshi, Date, Hiroshi

“…Background Pathological stage (pStage) and histological subtype are strong determinants of the treatment strategy for non-small cell lung cancer (NSCLC)…”
Get full text

Focal ground-glass opacity detected by low-dose helical CT by Nakata, Masao, Saeki, Hideyuki, Takata, Ichiro, Segawa, Yoshihiko, Mogami, Hiroshi, Mandai, Koichi, Eguchi, Kenji

“…Focal ground-glass opacity (GGO) has been detected increasingly by low-dose helical CT. Although focal GGO suggests in situ neoplastic lesion in the peripheral…”
Get more information

Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer by Sakaeda, Kanako, Kurose, Koji, Matsumura, Yuki, Muto, Satoshi, Fukuda, Minoru, Sugasaki, Nanae, Fukuda, Masaaki, Takemoto, Shinnosuke, Taniguchi, Hirokazu, Masuda, Takeshi, Shimizu, Katsuhiko, Kataoka, Yuki, Irino, Yasuhiro, Sakai, Yumiko, Atarashi, Yusuke, Yanagida, Masatoshi, Hattori, Noboru, Mukae, Hiroshi, Nakata, Masao, Kanda, Eiichiro, Oga, Toru, Suzuki, Hiroyuki, Oka, Mikio

“…[Display omitted] •NY-ESO-1 and XAGE1 cancer/testis antigens are highly immunogenic in NSCLC patients.•NY-ESO-1/XAGE1 Abs are potentially antitumor B-cell and…”
Get full text

Surgical Treatments for Multiple Primary Adenocarcinoma of the Lung by Nakata, Masao, Sawada, Shigeki, Yamashita, Motohiro, Saeki, Hideyuki, Kurita, Akira, Takashima, Shigemitsu, Tanemoto, Kazuo

“…The aim of this study was to identify the clinical characteristics of multiple primary adenocarcinomas and to evaluate the efficacy of surgical treatments…”
Get full text

Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis by MAEDA, AI, NAKATA, MASAO, YASUDA, KOICHIRO, YUKAWA, TAKURO, SAISHO, SHINSUKE, OKITA, RIKI, HIRAMI, YUJI, SHIMIZU, KATSUHIKO

“…Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis. Several studies have reported that genomic VEGF polymorphisms may…”
Get full text

Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701 by Soh, Junichi, Okumura, Norihito, Nakata, Masao, Nakamura, Hiroshige, Fukuda, Minoru, Kataoka, Masafumi, Kajiwara, Shinsuke, Sano, Yoshifumi, Aoe, Motoi, Kataoka, Kazuhiko, Hotta, Katsuyuki, Matsuo, Keitaro, Toyooka, Shinichi, Date, Hiroshi

“…The aim of this multicenter study was to determine the appropriate administration schedule for S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in…”
Get full text

Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001 by Okumura, Norihito, Sonobe, Makoto, Okabe, Kazunori, Nakamura, Hiroshige, Kataoka, Masafumi, Yamashita, Motohiro, Nakata, Masao, Kataoka, Kazuhiko, Yamashita, Yoshinori, Soh, Junichi, Yoshioka, Hiroshige, Hotta, Katsuyuki, Matsuo, Keitaro, Sakamoto, Junichi, Toyooka, Shinichi, Date, Hiroshi

“…Background This multicenter study evaluated the feasibility of novel adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent, long-term…”
Get full text

Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma by Shimizu, Katsuhiko, Maeda, Ai, Yukawa, Takuro, Nojima, Yuji, Saisho, Shinsuke, Okita, Riki, Nakata, Masao

“…The maximal standardized uptake value (SUVmax) on fluorodeoxyglucose-positron emission tomography (FDG-PET) for primary tumors is correlated with…”
Get full text

Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer by Shimizu, Katsuhiko, Yukawa, Takuro, Hirami, Yuji, Okita, Riki, Saisho, Shinsuke, Maeda, Ai, Yasuda, Koichiro, Nakata, Masao

“…The purpose of this study was to clarify the distribution of epidermal growth factor receptor ( EGFR ) mutations between primary tumors (PT) and metastatic…”
Get full text